Tue, May 13, 12:15 PM (34 days ago)
**Coya Therapeutics, Inc. (COYA) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Collaboration revenue increased by $131,046,000 (103%) to $257,884,000 in Q1 2025 from $126,838,000 in Q1 2024. - **Profit Margins:** COYA reported a net loss of $7,306,757,000 in Q1 2025, a 44% increase in net loss compared to $5,051,913,000 in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $2,828,275,000 in Q1 2025, a significant decrease compared to the net cash provided by operating activities of $2,145,874,000 in Q1 2024. - **Earnings Changes:** The net loss per share increased to $0.44 in Q1 2025 from $0.35 in Q1 2024. **Key Performance Metrics:** - **Operating Expenses:** Total operating expenses increased by $2,324,966,000 (41%) to $7,934,806,000 in Q1 2025 from $5,609,840,000 in Q1 2024. - **Research & Development (R&D):** R&D expenses increased by $2,075,917,000 (66%) to $5,214,076,000, driven by preclinical and internal R&D activities. - **General & Administrative (G&A):** G&A expenses increased by $274,049,000 (11%) to $2,713,890,000, primarily due to stock-based compensation and investor relations. - **Cash & Cash Equivalents:** As of March 31, 2025, COYA had $35,530,624,000 in cash and cash equivalents, down from $38,339,762,000 at the end of 2024. **Trends & Uncertainties:** - **Revenue Growth:** Collaboration revenue growth is driven by the DRL Development Agreement, with significant milestones and royalties expected in the future. - **Expense Management:** COYA expects continued increases in R&D and G&A expenses as it advances its product candidates through clinical trials and prepares for potential commercialization. - **Funding Requirements:** COYA anticipates needing substantial additional capital to fund operations and future growth, with no assured sources of financing. - **Market Risks:** COYA faces risks associated with the biotechnology industry, including regulatory, competitive, and economic factors. **Future Operations Impact:** - **Product Pipeline:** COYA's focus on Treg-enhancing biologics, exosomes, and cell therapy positions it for potential growth in treating neurodegenerative, autoimmune, and metabolic diseases. - **Collaborations:** Strategic partnerships, such as the DRL Development Agreement, are crucial for COYA's financial health and operational success. - **Regulatory Milestones:** Achieving regulatory approvals and milestones will be critical for COYA's future revenue generation and market positioning.